165 related articles for article (PubMed ID: 27990485)
1. The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation.
Do Nguyen HT; Wong G; Chapman JR; McDonald SP; Coates PT; Watson N; Russ GR; D'Orsogna L; Lim WH
Transplant Direct; 2016 Dec; 2(12):e120. PubMed ID: 27990485
[TBL] [Abstract][Full Text] [Related]
2. HLA molecular epitope mismatching and long-term graft loss in pediatric heart transplant recipients.
Sullivan PM; Warner P; Kemna MS; Albers EL; Law SP; Weiss NS; Law YM
J Heart Lung Transplant; 2015 Jul; 34(7):950-7. PubMed ID: 25727771
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigen eplet mismatching is associated with increased risk of graft loss and rejection after pediatric heart transplant.
Albers EL; Friedland-Little JM; Hong BJ; Kemna MS; Warner P; Law YM
Pediatr Transplant; 2022 Feb; 26(1):e14126. PubMed ID: 34476876
[TBL] [Abstract][Full Text] [Related]
4. Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss.
Sapir-Pichhadze R; Zhang X; Ferradji A; Madbouly A; Tinckam KJ; Gebel HM; Blum D; Marrari M; Kim SJ; Fingerson S; Bashyal P; Cardinal H; Foster BJ
Kidney Int; 2020 Apr; 97(4):778-785. PubMed ID: 32059998
[TBL] [Abstract][Full Text] [Related]
5. Eplet matching in pediatric heart transplantation: The SickKids experience.
Cardoso B; Wang J; Kiernan J; Dipchand AI
J Heart Lung Transplant; 2022 Oct; 41(10):1470-1477. PubMed ID: 35933296
[TBL] [Abstract][Full Text] [Related]
6. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
[TBL] [Abstract][Full Text] [Related]
7. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
[TBL] [Abstract][Full Text] [Related]
8. HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients.
Lim WH; Chapman JR; Coates PT; Lewis JR; Russ GR; Watson N; Holdsworth R; Wong G
Clin J Am Soc Nephrol; 2016 May; 11(5):875-883. PubMed ID: 27034399
[TBL] [Abstract][Full Text] [Related]
9. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
Yanyiam P; Kantachuvesiri S; Thammanichanond D
Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
[TBL] [Abstract][Full Text] [Related]
10. Human Leukocyte Antigen-Based Risk Stratification in Heart Transplant Recipients-Implications for Targeted Surveillance.
Nilsson J; Ansari D; Ohlsson M; Höglund P; Liedberg AS; Smith JG; Nugues P; Andersson B
J Am Heart Assoc; 2019 Aug; 8(15):e011124. PubMed ID: 31339067
[TBL] [Abstract][Full Text] [Related]
11. The value of high-resolution HLA in the perioperative period of non-sensitized lung transplant recipients.
Zhang J; Liu D; Zhang C; Zhou M; Lv J; Wang H; Yang H; Fan L; Wu B; Chen J
Ann Transl Med; 2020 Feb; 8(3):37. PubMed ID: 32154282
[TBL] [Abstract][Full Text] [Related]
12. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
Bryan CF; Chadha V; Warady BA
Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
[TBL] [Abstract][Full Text] [Related]
13. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches.
Bunnapradist S; Hong A; Lee B; Takemoto SK
Transplant Proc; 2005 Mar; 37(2):886-8. PubMed ID: 15848565
[TBL] [Abstract][Full Text] [Related]
14. Degree of HLA class II eplet mismatch load improves prediction of antibody-mediated rejection in living donor kidney transplantation.
Tafulo S; Malheiro J; Santos S; Dias L; Almeida M; Martins S; Pedroso S; Mendes C; Lobato L; Castro-Henriques A
Hum Immunol; 2019 Dec; 80(12):966-975. PubMed ID: 31604581
[TBL] [Abstract][Full Text] [Related]
15. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study.
Sapir-Pichhadze R; Tinckam K; Quach K; Logan AG; Laupacis A; John R; Beyene J; Kim SJ
Am J Transplant; 2015 Jan; 15(1):137-48. PubMed ID: 25521856
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen, allele, and eplet mismatches in liver transplantation; observations from a small, single center cohort.
Forner D; Liwski R; Alwayn I
Hum Immunol; 2018 Mar; 79(3):154-159. PubMed ID: 29289739
[TBL] [Abstract][Full Text] [Related]
17. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker.
Kosmoliaptsis V; Bradley JA; Sharples LD; Chaudhry A; Key T; Goodman RS; Taylor CJ
Transplantation; 2008 Jun; 85(12):1817-25. PubMed ID: 18580476
[TBL] [Abstract][Full Text] [Related]
18. Implementation of molecular matching in transplantation requires further characterization of both immunogenicity and antigenicity of individual HLA epitopes.
Bezstarosti S; Kramer CSM; Claas FHJ; de Fijter JW; Reinders MEJ; Heidt S
Hum Immunol; 2022 Mar; 83(3):256-263. PubMed ID: 34963506
[TBL] [Abstract][Full Text] [Related]
19. Different eplet software programs give discordant and incorrect results: An analysis of HLAMatchmaker vs Fusion Matchmaker Eplet calling software.
Tassone G; De Santis D; Vukovic I; Downing J; Martinez OP; D'Orsogna LJ
HLA; 2020 Jul; 96(1):52-63. PubMed ID: 32281731
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity.
Wiebe C; Kosmoliaptsis V; Pochinco D; Taylor CJ; Nickerson P
Transplantation; 2018 Aug; 102(8):1338-1343. PubMed ID: 29443827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
